IBM trades against a final fair-value range of $239.16-$326.13, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $239, high $326, with mid-point at $283.
Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$283
Margin of safety
+18.7%
Confidence
88/100
Moat
6.5/10
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
$229.76Price
Low $239.16
Mid $282.5
High $326.13
IBM trades against a final fair-value range of $239.16-$326.13, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
High switching costs for legacy
High switching costs for legacy enterprise infrastructure
Mission-critical hybrid cloud deployments via
Mission-critical hybrid cloud deployments via Red Hat
Reverse DCF for IBM (IBM) backs out the revenue or earnings growth rate the current share price implies, holding terminal value, margin, and discount-rate assumptions constant.
We compare the implied rate to our own forecast deceleration curve and to the historical five-year actual. When the implied rate exceeds the realistic ceiling, the price is pricing in optimism the business has not yet demonstrated.
Reverse DCF uses cost of equity (Ke), not WACC, to stay consistent with the EPS-based forward valuation models. Ke is derived from CAPM with adjusted beta; the strict and moderate variants are documented in the assumption ledger.
When the implied growth rate is below our forecast, the market is underpricing the business; when it is above, the market is overpricing. The reverse-DCF read is one of four lenses that feed the composite fair-value range and the rating band.
FAQ
IBM — frequently asked questions
Based on our latest analysis, IBM looks meaningfully undervalued. The current price is $230 versus a composite fair-value midpoint of $283 (range $239–$326), which implies roughly 22.9% upside to the midpoint.
Our composite fair-value range for IBM is $239–$326, with a midpoint of $283. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for IBM's archetype.
Our current rating for IBM is Buy with a confidence score of 88/100. IBM is rated Buy at $229.76 versus the reconciled fair value midpoint of $282.50, implying +22.95% upside/downside. Confidence is separately disclosed at 88/100. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for IBM are: Hyperscaler Compression; Consulting Collapse; Gen AI Disruption. The single biggest risk is Hyperscaler Compression: Cloud providers aggressively price hybrid solutions, eroding IBM's software operating margin expansion.
Our current rating for IBM is Buy, issued with a confidence score of 88/100 and a moat score of 6.5/10. The rating reflects the composite fair-value range ($239–$326) versus the current price of $230.
IBM is classified as a mature-dividend stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for IBM.
